GANNET53

We established a highly efficient scientific consortium with a strong track record of proven capability and manpower to perform this multicentre clinical trial and assess our innovative therapeutic concept in this deadly disease. Our consortium consists of nation-wide clinical trial groups in gynaecological oncology and high-volume university centres as well as noted p53 scientists and 3 innovative SMEs. Since ovarian cancer is defined as a rare cancer, a scale at the European level is crucial for the planned clinical trial... The GANNET53 consortium consists of 22 partners from 5 European countries (Austria, Belgium, France, Germany and Italy). We are a group of passionate collaborates and an interdisciplineary team that has one common goal: improve the life of patients suffering from ovarian cancer.

Registration numbers: HRB106070B (W)

VAT numbers: DE 814 804 614

Primary location: Innsbruck Austria